-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $329

Benzinga·05/15/2026 17:26:38
Listen to the news
Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $324 to $329.